Mogam Biotechnology Research Institute - As a nonprofit R&D foundation, Mogam Biotechnology Research Institute is constantly striving to function as a research institute with drug development capabilities based on scientific investigation and understanding of life phenomena.


H > About > History

History of MOGAM

“Y.S. Huh knew that there was more to conquer in Korea than hepatitis B. So he built an institute to do it."

The MOGAM Institute (MI) was established in 1984 by Dr. Young-sup Huh. It is Korea’s first privately owned non-profit research institute. The history of the MI begins when Dr. Huh was studying in Germany in the 1960s. While overseas, he was dismayed with the quality of medicines available in Korea compared to Western countries. After returning to Korea in 1970, he dedicated his life to creating a sustainable biopharmaceutical industry in Korea for the benefit of Koreans. Since then, his work led to the development of the third in the world Hepatitis B vaccine, the first Epidemic hemorrhagic fever vaccine, and the second chickenpox vaccine. His work had implications that crossed borders and improved lives worldwide.

In 1984, Dr. Huh founded the MI using all of the profit generated from the successful development of the Hepatitis B vaccine by Green Cross Pharmaceuticals. Since its inception, MOGAM has made significant contributions to Korea’s biomedical industry by successfully producing vaccines, diagnostic kits, and important recombinant proteins. Our mission is to help those suffering from disease by understanding life’s underlying cellular and molecular processes and using this knowledge to develop innovative therapies.

The MI is the place for creative thought and collaboration to bridge between academic institutions and industry. Today the Institute’s research is guided by 8 faculty investigators and more than 70 scientists from all over the world. Since the institute’s inception in 1984, our scientists have registered over 190 patents and published some of the groundbreaking scientific papers in leading journals. We dare to make discoveries for the world to improve the quality of life for all.


Dr. Young-sup Huh, founder of Green Cross Corp., who succeeded in developing the first hepatitis B vaccine in Korea, established the MOGAM Institute in 1984. With philanthropy at its core, MOGAM was created with proceeds from the successful development of the hepatitis B vaccine and is Korea's first privately-funded non-profit research institute. The institute's mission is to study the cellular and molecular basis of disease in order to develop novel therapies.

Discovery facts

MOGAM scientists are credited with numerous important achievements that help prevent, diagnose, and treat disease. We have developed recombinant vaccines against Hepatitis B, Epidemic Hemorrhagic Fever, and Varicella (shingles); we have developed diagnostic reagents for the Human Immunodeficiency Virus (HIV) and Hepatitis C Virus; and we have developed therapeutics such as interferon and Granulocyte Colony Stimulating Factor (G-CSF). Our scientists have registered over 190 patents since the institute was established in 1984.

Research areas

The major areas of study at MOGAM are cancer, infectious diseases, and deficiency diseases. MOGAM research elucidates disease processes and provides potential new therapies for a range of diseases--from cancer to neurodegenerative diseases such as Alzheimer's. The research is guided by 8 principal investigators and about 80 staff scientists.